PET/Computed Tomography Using New Radiopharmaceuticals in Targeted Therapy
- 3 July 2015
- journal article
- review article
- Published by Elsevier in PET Clinics
- Vol. 10 (4) , 495-505
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumorEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- PET/CT imaging of neuroendocrine tumors with 68 Gallium-labeled somatostatin analogues: An overview and single institutional experience from IndiaIndian Journal of Nuclear Medicine, 2014
- Diagnostic accuracy of 68Ga-DOTANOC PET/CT imaging in pheochromocytomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Gallium-68-DOTA-NOC PET/CT of Patients With Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Single-Center StudyAmerican Journal of Roentgenology, 2011
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin AnalogsNeuroendocrinology, 2009
- Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?European Journal of Nuclear Medicine and Molecular Imaging, 2007
- Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumoursActa Oncologica, 2007
- 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5European Journal of Nuclear Medicine and Molecular Imaging, 2004
- Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.Endocrine-Related Cancer, 2003